Slovenian Pharma Stock Underpriced, Say KAD and SOD
Ljubljana, 19 September - The two largest individual stock holders of Slovenian pharmaceutical company Lek, the Pension Fund Management (KAD) and the Restitution Fund (SOD), will not back the changes to Lek's company statute at the assembly on 27 September unless Swiss buyer Novartis offers a higher takeover price than has been announced. The changes to the statute are necessary for Novartis's acquisition of Lek.
The rest of this news item is available to subscribers.
The news item consists of 1.962 characters (without spaces) or 398 words words.
Buy the news item. Price: 2 tokens; on account: 0 tokens.